HC Wainwright Predicts Reduced Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN - Free Report) - Stock analysts at HC Wainwright reduced their Q4 2025 earnings estimates for shares of Legend Biotech in a research note issued on Wednesday, March 12th. HC Wainwright analyst M. Kapoor now expects that the company will earn $0.11 per share for the quarter, down from their prior estimate of $0.12. HC Wainwright has a "Buy" rating and a $75.00 price objective on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.46. The company had revenue of $186.50 million for the quarter, compared to analyst estimates of $179.00 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm's quarterly revenue was up 134.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) EPS.

Several other equities research analysts have also recently issued reports on LEGN. Piper Sandler reissued an "overweight" rating and issued a $78.00 target price on shares of Legend Biotech in a research report on Monday, December 30th. Guggenheim reissued a "neutral" rating on shares of Legend Biotech in a research report on Wednesday, March 12th. Cantor Fitzgerald reissued an "overweight" rating and issued a $83.00 target price on shares of Legend Biotech in a research report on Monday, December 9th. Morgan Stanley decreased their target price on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating on the stock in a research report on Monday. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $86.00 target price on shares of Legend Biotech in a research report on Monday, December 9th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $79.17.

Remove Ads

Legend Biotech Trading Down 0.2 %

NASDAQ:LEGN traded down $0.06 on Friday, reaching $37.88. The stock had a trading volume of 605,102 shares, compared to its average volume of 1,171,386. The company has a market cap of $6.92 billion, a price-to-earnings ratio of -39.87 and a beta of 0.19. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90. The firm's fifty day moving average is $35.75 and its two-hundred day moving average is $40.61. Legend Biotech has a 12-month low of $30.17 and a 12-month high of $65.45.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LEGN. Suvretta Capital Management LLC acquired a new position in Legend Biotech during the fourth quarter valued at approximately $113,767,000. Deerfield Management Company L.P. Series C purchased a new stake in shares of Legend Biotech during the fourth quarter valued at approximately $50,493,000. Braidwell LP raised its stake in shares of Legend Biotech by 93.2% during the fourth quarter. Braidwell LP now owns 2,977,951 shares of the company's stock valued at $96,903,000 after purchasing an additional 1,436,400 shares during the period. Invesco Ltd. raised its stake in shares of Legend Biotech by 44.7% during the fourth quarter. Invesco Ltd. now owns 3,309,971 shares of the company's stock valued at $107,706,000 after purchasing an additional 1,022,365 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in shares of Legend Biotech by 155.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,505,562 shares of the company's stock valued at $48,991,000 after purchasing an additional 915,891 shares during the period. 70.89% of the stock is owned by institutional investors and hedge funds.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).